An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine

J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):236-8. doi: 10.1097/01.qai.0000143037.70120.fc.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Alkynes
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Benzoxazines
  • Blood Glucose / metabolism
  • Cross-Sectional Studies
  • Cyclopropanes
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism*
  • Humans
  • Lipids / blood
  • Nevirapine / adverse effects*
  • Nevirapine / therapeutic use
  • Oxazines / adverse effects*
  • Oxazines / therapeutic use
  • Reverse Transcriptase Inhibitors / adverse effects*

Substances

  • Alkynes
  • Benzoxazines
  • Blood Glucose
  • Cyclopropanes
  • Lipids
  • Oxazines
  • Reverse Transcriptase Inhibitors
  • Nevirapine
  • efavirenz